Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)

Phase 3

Recruiting

• Conditions: Gynecologic Cancer; Iron-deficiency; Anemia
• Interventions: Drug: Ferric derisomaltose; Drug: Placebo

• Registration Number: NCT05407987
• Lead Sponsor: AHS Cancer Control Alberta

Brief Summary

Iron deficiency has been reported in approximately 35% of patients with a gynecologic malignancy. Blood transfusions are known to be immunosuppressive and carry immediate and long-term risks. Pre-operative blood transfusion in gynecologic oncology patients is associated with higher rates of surgical site infection, length of stay, composite morbidity, cancer recurrence, and mortality. Pre-operative intravenous iron formulations have been shown in benign gynecology and other surgical specialities to increase pre-operative hemoglobin and decrease post-operative transfusion rates.

This is a randomized double-blinded clinical trial evaluating the effects of treating patients undergoing gynecologic oncology surgery with intravenous ferric derisomaltose to correct pre-operative iron-deficiency anemia.

The study aims to assess the effectiveness of preoperative ferric derisomaltose/iron isomaltoside compared to placebo in correcting preoperative hemoglobin in patients undergoing surgery for gynecologic malignancy.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-06-01
• Study First Submitted QC: 2022-06-03
• Study First Posted: 2022-06-07
• Status Verified: 2025-04
• Study Start: 2025-04-08
• Last Update Submitted: 2025-04-23
• Last Update Posted: 2025-04-25
• Primary Completion: 2026-12-30
• Study Completion: 2026-12-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 82

Inclusion Criteria

1. Signed written informed consent prior to initiation of any study specific activities/procedures.

2. Age ≥ 18 years old.

3. Patients undergoing elective major surgery on the gynecologic oncology service with the following criteria will be considered for inclusion:

   1. The indication for the operation may be for suspected or proven gynecologic malignancy.
   2. Major surgery is defined as an operation of a duration of 1 hour or greater, with an Aletti complexity score of at least 1.
   3. The expected time from recruitment to surgery is 28-90 days.

4. Screening haemoglobin less than 120 g/L and transferrin saturation (TSAT) <20%.

5. Randomization and administration of study infusion a minimum of 21 days and maximum 90 days before planned operation.

6. Negative pregnancy test for women of childbearing potential (WOCBP) (within 7 days prior to treatment).

7. WOCBP must adhere to the contraception requirement from screening throughout the study period until 6 weeks post treatment.

8. Laboratory data used for determination of eligibility (Hemoglobin and Transferrin saturation) at the baseline visit must not be older than 4 weeks.

Exclusion Criteria

1. Known history of acquired iron overload, or family history of haemochromatosis or thalassemia, or TSAT >50%.

2. Known alternative cause for anemia (e.g., B12 or folate deficiency, or haemoglobinopathy).

3. Known hypersensitivity to Ferric derisomaltose/iron isomaltoside (Monoferric®) or its excipients.

4. Temperature >38C or patient on non-prophylactic antibiotics.

5. Known chronic liver disease or active hepatitis.

6. Received erythropoietin or IV iron therapy within previous 12 weeks prior to planned study drug treatment.

7. Alanine transaminase (ALT) or aspartate transaminase (AST) above three times the upper limit of normal (ULN) range.

8. Immunosuppressive therapy (for solid organ transplant), or renal dialysis (current, or planned within next 12 months following treatment with study drug or placebo).

9. Unfit for elective surgery.

10. Pregnancy or lactation.

11. Unable to fully comprehend and/or perform study procedures and patients with psychiatric illness/social situations/substance abuse that would limit compliance with study requirements.

12. Cervical cancer with a clinical stage of 2A or greater.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Iron Therapy Arm	Ferric derisomaltose	500 or 1000mg of IV Ferric Derisomaltose in 100mL normal saline will be administered intravenously over 1 hour. Participants with bodyweight \<50kg will receive 500mg, participants with bodyweight \>50kg will receive 1000mg to ensure no patient exceeds the manufacturer's recommended dose of 20mg/kg bodyweight.
Placebo Arm	Placebo	100mL of normal saline will be administered intravenously over 1 hour between 21 and 90 days preceding surgical intervention.

Primary Outcome Measures

Name	Time	Method
Mean preoperative haemoglobin concentration	Haemoglobin concentration will be measured at baseline and 3 days prior to surgery after treatment with Ferric Derisomaltose	To determine the effect of IV iron supplementation provided at least 21 days prior to surgery for gynecologic malignancy on mean preoperative haemoglobin concentration (in g/L)in patients with iron deficiency anemia compared to those patients without preoperative IV iron supplementation.

Secondary Outcome Measures

Name	Time	Method
Mean postoperative haemoglobin concentration	Haemoglobin concentration will be measured at 28 and 60 days after surgery	The effect of IV iron supplementation provided prior to surgery for gynecologic malignancy on mean hemoglobin concentration after the completion of surgery which will be assessed by measuring blood hemoglobin levels
Assessment of the requirement of postoperative blood transfusion	Day 0 to 28 days following surgery	The number of participants requiring blood transfusion after completion of gynecologic surgery. A blood transfusion event is defined as receiving any volume of one unit or more than one unit of packed red cells or whole blood.
Mean Change in the Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scores	Baseline to 0-3 days prior to surgery and at 23-33 days postoperative	The FACT-An questionnaire is a 47-item, cancer specific questionnaire consisting of a core 27 items measuring 4 general domains physical well being (PWG), social/family (SWB), emotional well being (EWB) and Functional Well-Being (FWB) and an additional 20-item anemia questionnaire that measures fatigue associated items and 7 non-fatigue items. The scales are formatted on 1 to 4 pages for self-administration using a 5-point Likert rating scale (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a Bit and 4 = Very much). Also, general health related quality of life (HRQoL), the FACT-An measures the impact of fatigue and other anemia-related symptoms on patient functioning and is used to assess the effect of treatments in various therapeutic areas, including MDS.
Mean haemoglobin concentration at the time of surgery	Haemoglobin concentration will be measured at baseline and at the time of surgery after treatment with Ferric Derisomaltose	The effect of IV iron supplementation provided prior to surgery for gynecologic malignancy on mean haemoglobin concentration (in g/L) at the time of surgery.
Mean number of blood transfusions	Day 0 to 28 days following surgery	The mean number of blood transfusion (total number of units of packed red blood cells transfused ) after completion of gynecologic surgery
Postoperative Quality of Recovery(QoR)-15 questionnaire score	Post-operation day 1 (24 hours ± 12 hours following surgery)	Quality of life will be evaluated using Quality of Recovery(QoR)-15 questionnaire score at postoperative day 1 compared to baseline (minimum value : 0, maximum value : 150, the higher the score, the better the result)
Mean Change in Quality of life measured with the EQ5D5L (European Quality of Life Five Dimension) scores	Baseline to 0-3 days prior to surgery and at 23-33 days postoperative	Health-related quality of life will be measured using the EuroQol Five Dimensions (EQ-5D). The EQ-5D-5L is a valid extension of the 3-level questionnaire. It can be defined as a standardized non-disease specific value-based instrument to describe and value health-related quality of life. The instrument consists of two components: the EQ-5D descriptive system and the EQ visual analogue scale (EQ-VAS).The first part consists of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five response categories (no problems, slight problems, moderate problems, severe problems, and extreme problems), from which a single EQ-5D index score can be calculated ranging from 0 (dead) to 1 (perfect health). The EQ-VAS measures one's self-perceived health today on a vertical scale from 0 (worst imaginable health) to 100 (best imaginable health) on which participants have to indicate their current health.
Postoperative length of hospital stay	From Surgery date up to 60 days post surgery	Mean and median length of stay (in days) in hospital following surgery
Mean Change in Quality of life measured with the SF-36 scores	Baseline to 0-3 days prior to surgery and at 23-33 days postoperative	The SF-36 is a 36-item survey of health and well-being. The scale consists of eight domains: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health.; Minimum Value: 0 (worst outcome) Maximum Value: 100 (best outcome)
Clinical surgical site infection	within 28 days following surgery	Rate of participants presenting with clinical surgical site infection will be measured post-operation.
Clinical surgical complications	within 28 days following surgery	Proportion of participants experiencing any complication post-operatively
Rate of hospital readmission	from discharge date to 28 days post surgery	Proportion of participants requiring re-admission to hospital following surgery after initial discharge

Trial Locations

Locations (1)

Arthur J.E. Child Comprehensive Cancer Centre; 🇨🇦 Calgary, Alberta, Canada